SILVIA JIMENEZ-MORALES

Dr. SILVIA JIMENEZ-MORALES

National Institute of Genomic Medicine, Mexico.
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CACarlos Jhovani Pérez Amado
Carlos Jhovani Pérez Amado
ABAmellalli Bazan-Cordoba
Amellalli Bazan-Cordoba
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
Cancer is a serious health problem with a high mortality rate worldwide. Given the relevance of mitochondria in numerous physiological and pathological mechanisms, such as adenosine triphosphate (ATP) synthesis, apoptosis, metabolism, cancer progression and drug resistance, mitochondrial genome (mtDNA) analysis has become of great interest in the study of human diseases, including cancer. To date, a high number of variants and mutations have been identified in different types of tumors, which coexist with normal alleles, a phenomenon named heteroplasmy. This mechanism is considered an intermediate state between the fixation or elimination of the acquired mutations. It is suggested that mutations, which confer adaptive advantages to tumor growth and invasion, are enriched in malignant cells. Notably, many recent studies have reported a heteroplasmy-shifting phenomenon as a potential shaper in tumor progression and treatment response, and we suggest that each cancer type also has a unique mitochondrial heteroplasmy-shifting profile. So far, a plethora of data evidencing correlations among heteroplasmy and cancer-related phenotypes are available, but still, not authentic demonstrations, and whether the heteroplasmy or the variation in mtDNA copy number (mtCNV) in cancer are cause or consequence remained unknown. Further studies are needed to support these findings and decipher their clinical implications and impact in the field of drug discovery aimed at treating human cancer.

Verified
Journal Article
Open access
PDF file
GCGabriela Marisol Cruz-Miranda
Gabriela Marisol Cruz-Miranda
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
DBDiego Bárcenas-López
Diego Bárcenas-López
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
Julian Ramírez-BelloJulian Ramírez-Bello
Julian Ramírez-Bello
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
Acute leukemia (AL) is the main type of cancer in children worldwide. Mortality by this disease is high in developing countries and its etiology remains unanswered. Evidences showing the role of the long non-coding RNAs (lncRNAs) in the pathophysiology of hematological malignancies have increased drastically in the last decade. In addition to the contribution of these lncRNAs in leukemogenesis, recent studies have suggested that lncRNAs could be used as biomarkers in the diagnosis, prognosis, and therapeutic response in leukemia patients. The focus of this review is to describe the functional classification, biogenesis, and the role of lncRNAs in leukemogenesis, to summarize the evidence about the lncRNAs which are playing a role in AL, and how these genes could be useful as potential therapeutic targets.

18 November 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
IAIvan Sammir Aranda-Uribe
Ivan Sammir Aranda-Uribe
CPCarlos Jhovani Pérez-Amado
Carlos Jhovani Pérez-Amado
JRJulian Ramírez-Bello
Julian Ramírez-Bello
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of the pediatric cases and 40–50% of the adult patients relapse during and after the treatment period. The potential mechanisms that cause relapse involve clonal evolution, innate and acquired chemoresistance, and the ability of ALL cells to escape the immune-suppressive tumor response. Currently, immunotherapy in combination with conventional treatment is used to enhance the immune response against tumor cells, thereby significantly improving the OS in patients with ALL. Therefore, understanding the mechanisms of immune evasion by leukemia cells could be useful for developing novel therapeutic strategies.

27 October 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CPCarlos Jhovani Pérez-Amado
Carlos Jhovani Pérez-Amado
HTHugo Tovar
Hugo Tovar
LGLaura Gómez-Romero
Laura Gómez-Romero
FBFredy Omar Beltrán-Anaya
Fredy Omar Beltrán-Anaya
VBVerónica Bautista-Piña
Verónica Bautista-Piña
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
Studies have suggested a potential role of somatic mitochondrial mutations in cancer development. To analyze the landscape of somatic mitochondrial mutation in breast cancer and to determine whether mitochondrial DNA (mtDNA) mutational burden is correlated with overall survival (OS), we sequenced whole mtDNA from 92 matched-paired primary breast tumors and peripheral blood. A total of 324 germline variants and 173 somatic mutations were found in the tumors. The most common germline allele was 663G (12S), showing lower heteroplasmy levels in peripheral blood lymphocytes than in their matched tumors, even reaching homoplasmic status in several cases. The heteroplasmy load was higher in tumors than in their paired normal tissues. Somatic mtDNA mutations were found in 73.9% of breast tumors; 59% of these mutations were located in the coding region (66.7% non-synonymous and 33.3% synonymous). Although the CO1 gene presented the highest number of mutations, tRNA genes (T,C, and W), rRNA 12S, and CO1 and ATP6 exhibited the highest mutation rates. No specific mtDNA mutational profile was associated with molecular subtypes of breast cancer, and we found no correlation between mtDNA mutational burden and OS. Future investigations will provide insight into the molecular mechanisms through which mtDNA mutations and heteroplasmy shifting contribute to breast cancer development.

1 November 2016 in Archives of Medical Research
Verified
Journal Article
Closed access
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
DBDiego Alberto Bárcenas-López
Diego Alberto Bárcenas-López
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE

18 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
AGAna Elena Gil-Hernández
Ana Elena Gil-Hernández
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
AFArturo Fajardo-Gutiérrez
Arturo Fajardo-Gutiérrez
AMAurora Medina-Sansón
Aurora Medina-Sansón
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study was to identify if overweight and obesity are predictors of early mortality and relapse in Mexican children with ALL. A multicenter cohort study was conducted. ALL children younger than 15 years old were included and followed-up during the first 24 months after diagnosis. Overweight and obesity were classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Early mortality and early relapses were the main outcomes. A total of 1070 children were analyzed. Overweight/obesity at diagnosis were predictors of early mortality (WHO: HR = 1.4, 95%CI:1.0–2.0; CDC: HR = 1.6, 95%CI:1.1–2.3). However, no associations between overweight (WHO: HR = 1.5, 95%CI:0.9–2.5; CDC: HR = 1.0; 95% CI:0.6–1.6) and obesity (WHO: HR = 1.5, 95%CI:0.7–3.2; CDC: HR = 1.4; 95%CI:0.9–2.3) with early relapse were observed. Overweight and obese patients embody a subgroup with high risk of dying during leukemia treatment.